This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.

RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.

Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.

On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.

From 21 January 2019,  a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.

Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).

Whooping cough is a dangerous disease for new born, unvaccinated babies. Starting at the end of 2019, the whooping cough vaccination will be offered nationwide to pregnant women.

RIVM welcomed the Director General of ANCSEP Tunisia, Mr Mechichi on 11 and 12 December 2018.

“RIVM is committed to being innovative, and becoming a key player in citizen science is fully in line with that goal,” says Danielle Timmermans, Chief Science Officer for Risk Communication at RIVM

On 7 November 2018, Raymond Cointe, Director-General of INERIS and Hans Brug, Director-General of RIVM, signed a Framework Agreement. RIVM has been working with the French National Institute f